Response to Comments
New England CEPAC

PDF cover

Obeticholic Acid: ICER’s Response to Comments (NASH)

ICER’s response to public comments received on Draft Evidence Reports reviewing the comparative clinical effectiveness and value of obeticholic acid (OcalivaTM, Intercept Pharmaceuticals, Inc.) for primary biliary cholangitis and nonalcoholic steatohepatitis.


View All Materials on this Topic or Go Back to View More Materials